Blockchain Registration Transaction Record

Silexion Therapeutics Reports Q3 Financial Results and Business Update

Silexion Therapeutics Corp. (NASDAQ: SLXN) reported its Q3 financial results and provided an update on recent business developments, including the completion of its business combination with Moringa Acquisition Corp. The company's progress with LODER™ and SIL-204 demonstrates its commitment to advancing RNA interference therapies for challenging cancers. The financial updates also provide valuable insight into Silexion's growth and strategic milestones.

This news matters as it highlights the significant progress made by Silexion Therapeutics in developing innovative RNA interference therapies for challenging cancers. The promising results of LODER™ and SIL-204 demonstrate the potential to improve treatment outcomes for patients with KRAS-driven cancers. The company's strategic milestones and financial updates provide valuable insight into its growth and commitment to advancing cancer therapeutics.